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the Treatment Costs of Innovative Drugs. Farmeconomia. Health economics and therapeutic 
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There was an error in Discussion section at page 36 in this article by Piantedosi et al. 
[Farmeconomia. Health economics and therapeutic pathways 2019; 20(1): 27‑41; https://doi.
org/10.7175/fe.v20i1.1376]. The online version has been corrected on June 5, 2019, as shown 
below.
The phrase «The final treatment costs will be at net of negotiation settlement and credit 
note» has been replaced by «Drug expenditure was calculated as the price payed by the local 
pharmacy per single dose multiplied by the actual quantity administered. Credit notes and 
national management agreement are not included».
We apologize for any inconvenience caused.
